



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

If the Application of: Jonathan M. J. Derry, William

Docket No.:

3198

C. Fanslow III and William C. Dougall

Group Art Unit: 1631

Serial No: 09/851,673

Examiner:

Smith, C.L.

Filed:

May 8, 2001

For:

METHODS FOR IDENTIFYING COMPOUNDS THAT ANTAGONIZE

CD40 SIGNALING (as amended)

RECEIVED

Mail Stop Non-Fee Amendment Commissioner of Patents P. O. Box 1450 Alexandria, VA 22313-1450

MAY 2 0 2003

TECH CENTER 1600/2900

## REPLACEMENT RESPONSE TO OFFICE ACTION AND AMENDMENT A

- **Introductory Comments** begin on page 2 of this paper
- Amendments to the Specification begin on page 3 of this paper.
- Amendments to the Claims are reflected in the listing of claims which begin on page 6 of this paper.
- **Remarks** begin on page 11 of this paper.
- Conclusions begin on page 19 of this paper.
- **Exhibit A**

## **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Non Fee Amendment; Commissioner for Patents; P.O. Box 1450, Alexandria, VA, on the date indicated below.


Elizabeth M. McCarthy

\_\_\_\_ Date: May 16, 2003





Application No.: 09/851,673 Replacement Response t dated May 16, 2003 Response to Notice of Non-Compliant Amendment (Voluntary Revised Practice) of April 29, 2003



This Response and Amendment is responsive to an Office Action having a mailing date of January 15, 2003. Claim 2 is being canceled and replaced by newly added claim 25; newly added claims 26 through 39 are also being added herein, as shown on the following pages. The specification is being amended as shown in this Response.

Applicants thank the Examiner for an opportunity to discuss this case in a telephone interview on April 11, 2003. As discussed during the telephone interview, applicants are amending the specification to correct obvious errors and render it clear to one of ordinary skill in the art. Claim 2 is being canceled and re-presented as new claim 25, which includes several changes discussed during the telephone interview (and discussed in more detail herein) to more particularly point out and distinctly claim what applicants regard as their invention. Applicants are also submitting herewith evidence that methods to identify antagonists of CD40 signaling possess utility in the eyes of those of ordinary skill in the art.

